These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22748612)

  • 1. Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices.
    Freedland SJ; Richhariya A; Wang H; Chung K; Shore ND
    Urology; 2012 Aug; 80(2):293-8. PubMed ID: 22748612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population.
    Velde NV; Wu EQ; Guo A; Lu M; Yu AP; Sharma H; Liu J; Fan CP; Shi L
    Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):79-84. PubMed ID: 21173792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
    Henk HJ; Kaura S
    J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers.
    Henk HJ; Kaura S
    J Med Econ; 2012; 15(1):185-94. PubMed ID: 22168786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of patients with prostate cancer receiving zoledronic acid or pamidronate for prevention of skeletal-related events.
    Sherer JT; Adamus AT
    Pharmacotherapy; 2007 Feb; 27(2):207-17. PubMed ID: 17253911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel.
    Saad F; Higano CS; Sartor O; Colombel M; Murray R; Mason MD; Tubaro A; Schulman C
    Clin Genitourin Cancer; 2006 Mar; 4(4):257-62. PubMed ID: 16729908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
    Saad F; McKiernan J; Eastham J
    Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE.
    Ryan CJ; Elkin EP; Cowan J; Carroll PR
    Cancer; 2007 Jul; 110(1):81-6. PubMed ID: 17516446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006.
    Sathiakumar N; Delzell E; Morrisey MA; Falkson C; Yong M; Chia V; Blackburn J; Arora T; Kilgore ML
    Prostate Cancer Prostatic Dis; 2011 Jun; 14(2):177-83. PubMed ID: 21403668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
    J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases.
    Hagiwara M; Delea TE; Saville MW; Chung K
    Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):23-7. PubMed ID: 23146970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care.
    Saad F; Olsson C; Schulman CC
    Eur Urol; 2004 Dec; 46(6):731-39; discussion 739-40. PubMed ID: 15548440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007).
    Nørgaard M; Jensen AØ; Jacobsen JB; Cetin K; Fryzek JP; Sørensen HT
    J Urol; 2010 Jul; 184(1):162-7. PubMed ID: 20483155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practice trends in the diagnosis and management of prostate cancer in the United States.
    Gee WF; Holtgrewe HL; Albertsen PC; Litwin MS; Manyak MJ; O'Leary MP; Painter MR
    J Urol; 1995 Jul; 154(1):207-8. PubMed ID: 7539862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone-directed treatments for prostate cancer.
    Saad F
    Hematol Oncol Clin North Am; 2006 Aug; 20(4):947-63. PubMed ID: 16861125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer.
    Reed SD; Radeva JI; Glendenning GA; Saad F; Schulman KA
    J Urol; 2004 Apr; 171(4):1537-42. PubMed ID: 15017215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies.
    Saad F; Colombel M
    Expert Rev Anticancer Ther; 2010 Dec; 10(12):1991-2002. PubMed ID: 21110764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.